US Stock MarketDetailed Quotes

CG Oncology (CGON)

Watchlist
  • 73.430
  • +7.090+10.69%
Close Apr 17 16:00 ET
  • 74.000
  • +0.570+0.78%
Post 19:47 ET
6.20BMarket Cap-35.30P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

CG Oncology (CGON) Income Statement

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2025
(Q4)Dec 31, 2025
(Q3)Sep 30, 2025
(Q2)Jun 30, 2025
(Q1)Mar 31, 2025
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
Total revenue
254.70%4.04M
409.21%2.32M
3,774.42%1.67M
0
-90.17%52K
458.33%1.14M
45,500.00%456K
377.78%43K
111K
172.68%529K
Operating revenue
254.70%4.04M
409.21%2.32M
3,774.42%1.67M
--0
-90.17%52K
458.33%1.14M
45,500.00%456K
377.78%43K
--111K
172.68%529K
Cost of revenue
4.65M
3.07M
1.58M
0
0
0
Gross profit
-153.29%-607K
-264.04%-748K
106.98%89K
458.33%1.14M
456K
43K
Operating expense
64.21%190.17M
24.53%47.95M
80.74%51.22M
87.73%48.74M
83.74%42.26M
108.08%115.81M
98.93%38.51M
101.67%28.34M
110.64%25.96M
131.95%23M
Selling and administrative expenses
118.16%73.53M
53.73%17.99M
167.71%23.33M
132.32%17.41M
155.51%14.79M
240.40%33.7M
288.10%11.71M
276.18%8.72M
200.48%7.49M
179.21%5.79M
-General and administrative expense
118.16%73.53M
53.73%17.99M
167.71%23.33M
132.32%17.41M
155.51%14.79M
240.40%33.7M
288.10%11.71M
276.18%8.72M
200.48%7.49M
179.21%5.79M
Research and development costs
42.07%116.64M
11.78%29.96M
42.11%27.88M
69.63%31.33M
59.60%27.47M
79.45%82.1M
64.01%26.8M
67.21%19.62M
87.86%18.47M
119.46%17.21M
Operating profit
-66.37%-190.77M
-27.99%-48.7M
-80.70%-51.13M
-88.53%-48.74M
-87.83%-42.2M
-106.80%-114.67M
-96.58%-38.05M
-101.49%-28.3M
-109.74%-25.85M
-131.14%-22.47M
Net non-operating interest income expense
12.42%29.93M
19.20%7.44M
-5.97%7.42M
5.42%7.32M
39.74%7.75M
285.63%26.62M
122.72%6.25M
245.69%7.89M
800.52%6.94M
430.02%5.54M
Non-operating interest income
12.42%29.93M
19.20%7.44M
-5.97%7.42M
5.42%7.32M
39.74%7.75M
285.63%26.62M
122.72%6.25M
245.69%7.89M
800.52%6.94M
430.02%5.54M
Other net income (expense)
-5,166.67%-152K
-983.33%-53K
-4,900.00%-100K
-150.00%-4K
155.56%5K
104.84%3K
250.00%6K
75.00%-2K
113.79%8K
-212.50%-9K
Other non- operating income (expenses)
-5,166.67%-152K
-983.33%-53K
-4,900.00%-100K
-150.00%-4K
155.56%5K
104.84%3K
250.00%6K
75.00%-2K
113.79%8K
-212.50%-9K
Income before tax
-82.87%-161M
-29.91%-41.31M
-114.69%-43.81M
-119.16%-41.43M
-103.45%-34.45M
-81.12%-88.04M
-92.07%-31.8M
-73.39%-20.41M
-62.77%-18.9M
-95.38%-16.93M
Income tax
Net income
-82.87%-161M
-29.91%-41.31M
-114.69%-43.81M
-119.16%-41.43M
-103.45%-34.45M
-81.12%-88.04M
-92.07%-31.8M
-73.39%-20.41M
-62.77%-18.9M
-95.38%-16.93M
Net income continuous Operations
-82.87%-161M
-29.91%-41.31M
-114.69%-43.81M
-119.16%-41.43M
-103.45%-34.45M
-81.12%-88.04M
-92.07%-31.8M
-73.39%-20.41M
-62.77%-18.9M
-95.38%-16.93M
Minority interest income
Net income attributable to the parent company
-82.87%-161M
-29.91%-41.31M
-114.69%-43.81M
-119.16%-41.43M
-103.45%-34.45M
-81.12%-88.04M
-92.07%-31.8M
-73.39%-20.41M
-62.77%-18.9M
-95.38%-16.93M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-82.87%-161M
-29.91%-41.31M
-114.69%-43.81M
-119.16%-41.43M
-103.45%-34.45M
-29.85%-88.04M
-41.39%-31.8M
-16.51%-20.41M
-22.83%-18.9M
-36.55%-16.93M
Basic earnings per share
-47.52%-2.08
-6.25%-0.51
-90.00%-0.57
-92.86%-0.54
-25.00%-0.45
90.99%-1.41
-35.49%-0.48
-8.74%-0.3
-15.51%-0.28
87.43%-0.36
Diluted earnings per share
-47.52%-2.08
-6.25%-0.51
-90.00%-0.57
-92.86%-0.54
-25.00%-0.45
90.99%-1.41
-35.49%-0.48
-8.74%-0.3
-15.51%-0.28
87.43%-0.36
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
--
--
(FY)Dec 31, 2025(Q4)Dec 31, 2025(Q3)Sep 30, 2025(Q2)Jun 30, 2025(Q1)Mar 31, 2025(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024
Total revenue 254.70%4.04M409.21%2.32M3,774.42%1.67M0-90.17%52K458.33%1.14M45,500.00%456K377.78%43K111K172.68%529K
Operating revenue 254.70%4.04M409.21%2.32M3,774.42%1.67M--0-90.17%52K458.33%1.14M45,500.00%456K377.78%43K--111K172.68%529K
Cost of revenue 4.65M3.07M1.58M000
Gross profit -153.29%-607K-264.04%-748K106.98%89K458.33%1.14M456K43K
Operating expense 64.21%190.17M24.53%47.95M80.74%51.22M87.73%48.74M83.74%42.26M108.08%115.81M98.93%38.51M101.67%28.34M110.64%25.96M131.95%23M
Selling and administrative expenses 118.16%73.53M53.73%17.99M167.71%23.33M132.32%17.41M155.51%14.79M240.40%33.7M288.10%11.71M276.18%8.72M200.48%7.49M179.21%5.79M
-General and administrative expense 118.16%73.53M53.73%17.99M167.71%23.33M132.32%17.41M155.51%14.79M240.40%33.7M288.10%11.71M276.18%8.72M200.48%7.49M179.21%5.79M
Research and development costs 42.07%116.64M11.78%29.96M42.11%27.88M69.63%31.33M59.60%27.47M79.45%82.1M64.01%26.8M67.21%19.62M87.86%18.47M119.46%17.21M
Operating profit -66.37%-190.77M-27.99%-48.7M-80.70%-51.13M-88.53%-48.74M-87.83%-42.2M-106.80%-114.67M-96.58%-38.05M-101.49%-28.3M-109.74%-25.85M-131.14%-22.47M
Net non-operating interest income expense 12.42%29.93M19.20%7.44M-5.97%7.42M5.42%7.32M39.74%7.75M285.63%26.62M122.72%6.25M245.69%7.89M800.52%6.94M430.02%5.54M
Non-operating interest income 12.42%29.93M19.20%7.44M-5.97%7.42M5.42%7.32M39.74%7.75M285.63%26.62M122.72%6.25M245.69%7.89M800.52%6.94M430.02%5.54M
Other net income (expense) -5,166.67%-152K-983.33%-53K-4,900.00%-100K-150.00%-4K155.56%5K104.84%3K250.00%6K75.00%-2K113.79%8K-212.50%-9K
Other non- operating income (expenses) -5,166.67%-152K-983.33%-53K-4,900.00%-100K-150.00%-4K155.56%5K104.84%3K250.00%6K75.00%-2K113.79%8K-212.50%-9K
Income before tax -82.87%-161M-29.91%-41.31M-114.69%-43.81M-119.16%-41.43M-103.45%-34.45M-81.12%-88.04M-92.07%-31.8M-73.39%-20.41M-62.77%-18.9M-95.38%-16.93M
Income tax
Net income -82.87%-161M-29.91%-41.31M-114.69%-43.81M-119.16%-41.43M-103.45%-34.45M-81.12%-88.04M-92.07%-31.8M-73.39%-20.41M-62.77%-18.9M-95.38%-16.93M
Net income continuous Operations -82.87%-161M-29.91%-41.31M-114.69%-43.81M-119.16%-41.43M-103.45%-34.45M-81.12%-88.04M-92.07%-31.8M-73.39%-20.41M-62.77%-18.9M-95.38%-16.93M
Minority interest income
Net income attributable to the parent company -82.87%-161M-29.91%-41.31M-114.69%-43.81M-119.16%-41.43M-103.45%-34.45M-81.12%-88.04M-92.07%-31.8M-73.39%-20.41M-62.77%-18.9M-95.38%-16.93M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -82.87%-161M-29.91%-41.31M-114.69%-43.81M-119.16%-41.43M-103.45%-34.45M-29.85%-88.04M-41.39%-31.8M-16.51%-20.41M-22.83%-18.9M-36.55%-16.93M
Basic earnings per share -47.52%-2.08-6.25%-0.51-90.00%-0.57-92.86%-0.54-25.00%-0.4590.99%-1.41-35.49%-0.48-8.74%-0.3-15.51%-0.2887.43%-0.36
Diluted earnings per share -47.52%-2.08-6.25%-0.51-90.00%-0.57-92.86%-0.54-25.00%-0.4590.99%-1.41-35.49%-0.48-8.74%-0.3-15.51%-0.2887.43%-0.36
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions Unqualified Opinion--------Unqualified Opinion--------
Market Insights
No. Symbol 20D % Chg
Sample Name
Sample Code
 +14.09%
Sample Name
Sample Code
 +3.93%
Sample Name
Sample Code
 +2.06%
4
United States Oil Fund LP
USO
-1.12%
5
United States Gasoline Fund Lp
UGA
-2.10%
View More
China Concept Stocks
No. Symbol 5D % Chg
Sample Name
Sample Code
 +22.28%
Sample Name
Sample Code
 +20.52%
Sample Name
Sample Code
 +19.71%
4
Zai Lab
ZLAB
+16.97%
5
Legend Biotech
LEGN
+16.57%
View More
Middle East conflict spreads to the stock market! How should investors respond?
Lebanon and Israel will implement a 10-day ceasefire! Iran's foreign minister, based on the Lebanon ceasefire agreement, announced the compl Show More
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
Hormuz, Term Structure and USO: Navigating the Energy Storm

- No more -